Applied Biosystems Introduces TaqMan® Drug Metabolism Assays
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Applied Biosystems has announced the launch of TaqMan®, Drug Metabolism Genotyping Assays for the detection and study of polymorphisms in the drug metabolism pathway.
There are 2,000 assays for the detection of genetic variants in 220 genes that code for drug metabolism enzymes.
Gene variants or polymorphisms in drug metabolism enzymes are important pharmaceutical biomarkers that play a key role in altering drug concentration levels and determining side effect profiles of drugs.
By characterising these polymorphisms, participants in clinical trials can be differentiated on a genetic basis into those who are likely to benefit from treatment and those who may experience adverse reactions.
The TaqMan Drug Metabolism Genotyping Assays are single-tube probe and primer sets for use on Applied Biosystems Real-Time PCR instruments, including the 7300, 7500, and 7900HT Real-Time PCR Systems.
There are 2,000 assays for the detection of genetic variants in 220 genes that code for drug metabolism enzymes.
Gene variants or polymorphisms in drug metabolism enzymes are important pharmaceutical biomarkers that play a key role in altering drug concentration levels and determining side effect profiles of drugs.
By characterising these polymorphisms, participants in clinical trials can be differentiated on a genetic basis into those who are likely to benefit from treatment and those who may experience adverse reactions.
The TaqMan Drug Metabolism Genotyping Assays are single-tube probe and primer sets for use on Applied Biosystems Real-Time PCR instruments, including the 7300, 7500, and 7900HT Real-Time PCR Systems.
